[{"orgOrder":0,"company":"AriBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Mirodenafil dihydrochloride","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"AriBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AriBio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AriBio \/ Not Applicable"},{"orgOrder":0,"company":"AriBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Mirodenafil dihydrochloride","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"AriBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AriBio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AriBio \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for Mirodenafil dihydrochloride

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : AR1001 (mirodenafil dihydrochloride) is an oral PDE5 inhibitor, small molecule drug candidate. It is being evaluated for the treatment of patients with Alzheimer's Disease.

                          Brand Name : AR1001

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          February 25, 2024

                          Lead Product(s) : Mirodenafil dihydrochloride

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : AR1001 is an oral PDE5 inhibitor, small molecule drug candidate. It is being evaluated for the treatment of patients with Alzheimer's Disease.

                          Brand Name : AR1001

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          November 14, 2023

                          Lead Product(s) : Mirodenafil dihydrochloride

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank